International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

T-cell subsets play a crucial role in orchestrating the immune response, including its dysregulation in autoimmune disorders. Understanding the intricate balance and functions of T-cell subsets is vital for developing targeted therapies for autoimmune diseases. This article explores the role of T-cell subsets in autoimmune disorders, their implications for therapy, and emerging treatment strategies [1].

Autoimmune disorders arise from a breakdown in immune tolerance, leading to the immune system mistakenly attacking healthy tissues and organs. T cells, a type of white blood cell, are central to this process, with different subsets exerting distinct roles in immune regulation and response. Understanding the contributions of T-cell subsets in autoimmune diseases is essential for unraveling their pathogenesis and developing effective therapeutic interventions.

Autoimmune disorders represent a complex group of diseases characterized by the immune system's aberrant response against the body's own tissues. This breakdown in immune tolerance leads to chronic inflammation, tissue damage, and a myriad of debilitating symptoms across various organs and systems. While the exact causes of autoimmune diseases remain elusive, growing evidence points to the dysregulation of T-cell subsets as a central player in their pathogenesis [2].

T cells, a type of lymphocyte, are key orchestrators of the immune response, playing critical roles in both immune surveillance and immune regulation. The diverse array of T-cell subsets, each with distinct functions and cytokine profiles, governs the delicate balance between protective immunity and self-tolerance. However, in autoimmune disorders, this balance is disrupted, leading to misguided T-cell responses that target healthy tissues and organs.

One of the pivotal subsets in autoimmune pathogenesis is the CD4+ T-cell population, commonly known as helper T cells. These cells are involved in coordinating immune responses by secreting cytokines that activate other immune cells, such as macrophages and B cells. Within the CD4+ T-cell subset, several subtypes have been implicated in autoimmune diseases [3]. Th1 cells produce interferon-gamma and tumor necrosis factor-alpha, driving cell-mediated immune responses and contributing to diseases like rheumatoid arthritis and multiple sclerosis. Th2 cells, on the other hand, promote humoral immunity and are associated with conditions such as asthma and allergic reactions.

Another critical subset, Th17 cells, has gained attention for their role in autoimmune inflammation. Th17 cells produce interleukin-17 (IL-17), a pro-inflammatory cytokine implicated in tissue damage and autoimmune conditions like psoriasis, rheumatoid arthritis, and inflammatory bowel disease. In contrast, regulatory T cells (Tregs) act as guardians of immune tolerance, suppressing excessive immune activation and preventing autoimmunity. Defects in Treg function or numbers have been observed in various autoimmune disorders, highlighting their importance in maintaining immune homeostasis.

Apart from CD4+ T cells, CD8+ T cells, also known as cytotoxic T cells, play a significant role in autoimmune pathology. These cells are responsible for directly targeting and eliminating infected or abnormal cells, including those expressing self-antigens in autoimmune settings. Dysregulated CD8+ T-cell responses have been implicated in autoimmune hepatitis, type 1 diabetes, and vitiligo, where they contribute to tissue destruction and disease progression.

Understanding the intricate interplay between T-cell subsets and their dysregulation in autoimmune disorders is essential for unraveling the underlying mechanisms driving these diseases. It also provides a foundation for developing targeted therapies that aim to restore immune balance, suppress pathogenic T-cell responses, and promote immune tolerance. From cytokine-targeted therapies to immune-modulating biologics and cell-based interventions, the therapeutic landscape for autoimmune diseases is rapidly evolving, offering hope for improved outcomes and quality of life for patients grappling with these complex conditions [4].

Discussion

CD4+ T cells: CD4+ T cells, also known as helper T cells, are pivotal in coordinating immune responses. In autoimmune disorders, subsets such as Th1, Th2, Th17, and regulatory T cells (Tregs) play critical roles. Th1 cells produce pro-inflammatory cytokines and are implicated in diseases like rheumatoid arthritis and type 1 diabetes. Th2 cells, on the other hand, promote antibody production and are involved in conditions like asthma and allergies. Th17 cells contribute to tissue inflammation and are associated with diseases such as multiple sclerosis and psoriasis. Tregs, characterized by their immunosuppressive function, play a crucial role in maintaining immune tolerance and preventing autoimmunity.

CD8+ T cells: CD8+ T cells, also called cytotoxic T cells, are responsible for directly targeting and killing infected or aberrant cells. In autoimmune disorders, dysregulated CD8+ T-cell responses can contribute to tissue damage and disease progression. For instance, in autoimmune hepatitis and vitiligo, CD8+ T cells target liver cells and melanocytes, respectively, leading to tissue destruction [5].

Therapeutic implications: Understanding the specific roles of T-cell subsets in different autoimmune disorders has paved the way for targeted therapeutic approaches. Strategies aimed at modulating T-cell responses include cytokine blockade, T-cell depletion therapies, and enhancing Treg function. Biologic agents targeting cytokines involved in T-cell activation, such as TNF-alpha and IL-17, have shown efficacy in conditions like rheumatoid arthritis and psoriasis. Additionally, therapies that enhance Treg activity, such as low-dose interleukin-2 (IL-2) therapy, hold promise in restoring immune tolerance and mitigating autoimmunity [6].

Conclusion

The role of T-cell subsets in autoimmune disorders is multifaceted, with distinct subsets contributing to immune dysregulation and tissue damage. Advances in understanding T-cell biology and the immune landscape of autoimmune diseases have spurred the development of targeted therapies that aim to restore immune balance and tolerance. While challenges such as treatment resistance and side effects persist, ongoing research and innovation in immunotherapy offer hope for improved outcomes and better management of autoimmune disorders. By unraveling the complexities of T-cell subsets and their implications for therapy, we move closer to personalized and effective treatments for individuals living with autoimmune conditions.

Acknowledgement

None

Conflict of Interest

None

References

1. Hoyer KK, Kuswanto WF, Gallo E, Abbas AK (2009) Distinct roles of helper T-cell subsets in a systemic autoimmune disease. Blood 113: 389-395.

Indexed at, Google Scholar, Crossref

2. Murphy KA, Bhamidipati K, Rubin SJ, Kipp L, Robinson WH, et al. (2019) Immunomodulatory receptors are differentially expressed in B and T cell subsets relevant to autoimmune disease. Clin Immunol 209: 108276.

Indexed at, Google Scholar, Crossref

3. Kortekaas Krohn I, Aerts J L, Breckpot K, Goyvaerts C, Knol E, et al. (2022) T‐cell subsets in the skin and their role in inflammatory skin disorders. Allergy 77: 827-842.

Indexed at, Google Scholar, Crossref

4. Mason D, Fowell D (1992) T-cell subsets in autoimmunity. Curr opin immunol 4: 728-732.

Indexed at, Google Scholar, Crossref

5. Grace PY, Chiang D, Song SJ, Hoyte EG, Huang J, et al. (2009) Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin immunol 131: 240-253.

Indexed at, Google Scholar, Crossref

6. Kumar V, Kono DH, Urban JL, Hood L (1989) The T-cell receptor repertoire and autoimmune diseases. Annu rev immunol 7: 657-682.

Indexed at, Crossref